Upload
others
View
6
Download
0
Embed Size (px)
Citation preview
PP
-GE
P-E
UR
-024
4 D
ate
of p
rep
ara
tio
n: M
arc
h 2
01
8
Pharmacoeconomics for pharmacists: a guide in infectious diseases
Paul Wade
Consultant Pharmacist Infectious Diseases
Directorate of infection, Guy’s & St Thomas’ NHS Foundation Trust
Clinical Senior Lecturer, King’s College, London
Disclosures
Gilead
ICNet
Merck
Novartis
Pfizer
Wyeth
Astellas
AstraZeneca
Baxter
Cardiome
Clinigen
Cubist
Eumedica
Honoraria, consultancy fees & speakers’ bureau fees from:
Global, regional, national importance
http://www.who.int/antimicrobial-resistance/global-action-plan/UpdatedRoadmap-Global-Framework-for-Development-Stewardship-to-
combatAMR_2017_11_03.pdf. Accessed March 2018; https://ecdc.europa.eu/sites/portal/files/media/en/publications/Publications/EU-guidelines-prudent-
use-antimicrobials.pdf. Accessed March 2018; http://media.dh.gov.uk/network/357/files/2013/03/CMO-Annual-Report-Volume-2-20111.pdf. Accessed March
2018; https://amr-review.org/sites/default/files/AMR%20Review%20Paper%20-
%20Tackling%20a%20crisis%20for%20the%20health%20and%20wealth%20of%20nations_1.pdf. Accessed March 2018.
AMR, antimicrobial resistance.
https://amr-review.org/sites/default/files/AMR%20Review%20Paper%20-
%20Tackling%20a%20crisis%20for%20the%20health%20and%20wealth%20of%20nations_1.pdf.
Accessed March 2018.
WHO priority pathogens
http://www.who.int/medicines/news/2017/world-running-out-antibiotics-WHO-
report/en/. Accessed March 2018.
ECDC data from 2014
https://ecdc.europa.eu/en/publications-data/antimicrobial-resistance-Europe.
Accessed March 2018.
Not just bacteria…
Increase in incidence of invasive candidiasis & candidaemia
Driven by increased usage of immunosuppressive modifying agents, invasive devices & aggressive surgery
Epidemiology of candida infections also changing
Move from albicans to non-albicans strains
Has impact on drug susceptibility & treatment response
Increasing resistance to azoles & echinocandins being seen
Mould infections (with mortality up around 50%) also increasing
Driven by increasing usage of echinocandins & non-mould active azoles
Difficult to diagnose IMI because clinical symptoms, signs, and radiographic manifestations are unspecific
IMI, invasive mould infections.
Enoch DA, et al. Methods Mol Biol. 2017;1508:17–65.
Impact of increasing infection & resistance
*Bacteria and fungus.
https://www.cdc.gov/drugresistance/pdf/ar-threats-2013-508.pdf.
Accessed March 2018.
Not just in complex, specialist areas…
https://www.cdc.gov/drugresistance/protecting_yourself_family.html.
Accessed March 2018.
How can we hope to control this?
https://www.cdc.gov/drugresistance/cdc_role.html. Accessed March 2018.
Case identification
Risk factor assessment
Screening
Infection control
Rapid diagnostics
Optimal treatment
Introduction of new drugs
Clatworthy AE, et al. Nature Chem Biol 2007;3:541–548;
Ventola CL. P T 2015;40:277–283.
The number of new antibiotics developed and approved
has decreased steadily over the past three decades
(although four new drugs were approved in 2014), leaving
fewer options to treat resistant bacteria.
Increasing resistance & increasing usage – increased need for new agents
• Significant increase in carbapenem & piperacillin–tazobactam usage over last decade
• Driven by increased prevalence of ESBLs1
• Dosing strategies may be influencing usage volumes – double-dose carbapenems
• There is limited evidence that usage is slowing
• Resistance to carbapenems will increase with increased use of carbapenems
• Ceftazidime–avibactam has demonstrated activity in vitro against two of the pathogen families listed in the critical group:2,3
• Carbapenem-resistant Pseudomonas aeruginosa
• Carbapenem-resistant, ESBL-producing Enterobacteriaceae
ARHAI, Committee on Antimicrobial Resistance and Hospital Acquired Infections; ESBL, extended-spectrum beta-lactamase; MDR, multi-drug resistant;
NHS, National Health Service; PHE, Public Health England; Pip/taz, piperacillin–tazobactam; R&D, research and development.
1. IMS; standard units; J1 infection class 2004 – 2014; 2. WHO publishes list of bacteria for which new antibiotics are urgently needed [press release].
2017; 3. Zavicefta SmPC 2017.
0
2000
4000
6000
8000
10000
12000
14000
2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
CBP Pip/Taz
UK
0
5000
10000
15000
20000
25000
30000
2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
CBP Pip/Taz
Germany
0
2000
4000
6000
8000
10000
12000
14000
16000
18000
2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
CBP Pip/Taz
Italy
0
20000
40000
60000
80000
100000
120000
140000
160000
180000
2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
CBP Pip/Taz
China
0
2000
4000
6000
8000
10000
12000
14000
16000
18000
2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
CBP Pip/Taz
Brazil
Pip/tazCarbapenem
Considerations in managed introduction into practice
• Drug costs
• Administration costs
• Oral v IV; infusion v bolus; intermittent v continuous infusion; administration time; nursing time; dose
& frequency
• Monitoring/safety costs
• Drug levels; ancillary tests/visits; preventative medicines; risk mitigation
• Diagnostics
• Drug susceptibility testing – availability, validation, costs
• Outcomes
• Clinical response (relapse/recurrence); LoS (OPAT?); ICU days; complications (ADRs, resistance,
ongoing care); QALYs
• External drivers/funding models
• Diagnostic tools for invasive fungal infections
ADRs, adverse drug reactions; ICU, intensive care unit; IV, intravenous; LoS, length of stay;
OPAT, outpatient parenteral antimicrobial therapy; QALY, Quality-adjusted life year.
Wade P. Speaker opinion.
Burden of resistance in Gram-negatives
Gram-negative infections:
• Increased severity of illness
• Greater hospital & AB costs
• Longer stay in hospital & ICU
Resistance in GN
• Increased costs ($30k v $80k)
• Increased LoS (13d v 29d)
• Increased ICU stay (1d v 13d)
• Increased mortality (11% v 23%)
AB, antibiotic; GN, Gram negative; ICU, intensive care unit; LoS, length of stay.
Maragakis LL, Crit Care Med 2010;38:S345–51; Evans HL, et al. Crit Care Med 2007;35:89–95; Kaye KS, Pogue JM.
Pharmacotherapy 2015;35:949–62; Sievert DM, et al. Infect Control Hospital Epidemiol 2013;34:1–4.
Burden associated with common bacterial infections
cIAI, complicated intra-abdominal infection; cUTI,
complicated urinary tract infection; ICU, intensive care
unit; NP, nosocomial pneumonia; VAP, ventilator-
acquired pneumonia.
1. Cattan P, et al. European Journal Of Clinical
Microbiology & Infectious Diseases 2002;21:787-793; 2.
Swenson BR, et al. Surg Infect (Larchmt). 2009;10:29–
39.3. Inui T, et al. Surgery. 2009;146(4):654-
661;discussion 661-652. 4. Lau WK, et al. Antimicrobial
Agents and Chemotherapy. 2006;50:3556–3561; 5.
Barie PS, et al. Surg Infect (Larchmt). 2004;5:269–280;
6. Montravers P, et al. Annals of Surgery.
2004;239:409–416; 7. Rocha Lde A, et al. The Brazilian
Journal Of Infectious Diseases 2008;12:80–85; 8.
Martin-Loeches I, et al. Intensive Care Medicine.
2013;39:672–681; 9. Suka M, et al. Infection Control and
Hospital Epidemiology 2007;28:307–313; 10.
Sandiumenge A, et al. Chest. 2011;140:643–651; 11.
Tellado JM, et al. Scand J Infect Dis. 2007;39:947–955;
12. Gastmeier P, et al. Infection Control and Hospital
Epidemiology 2007;28:466–472; 13. Micek ST, et al.
Critical Care (London, England). 2015;19:219; 14.
Dalfino L, et al. WJES. 2014;9:39; 15. Brown P, et al.
PharmacoEconomics. 2005;23:1123–1142; 15.
Zimlichman E, et al. JAMA internal medicine.
2013;173:2039–2046; 16. Kollef MH, et al. Infection
Control and Hospital Epidemiology 2012;33:250–256;
17. Bloom JD, et al. American Thoracic Society;
2011:A4122-A4122; 18. Kanj SS, Kanafani ZA. Mayo
Clinic proceedings. Mayo Clinic. 2011;86:250–259; 19.
Barie PS, et al. Surg Infect (Larchmt). 2004;5(4):
365–373.
Substantial clinical burden
cIAI: reported estimates range from 74 to 18.65 days in
hospital and 35 to 116 days in ICU
cUTI: scarce data available
HAP (inc. VAP): reported estimates range from 9.27 to 53.48
days in hospital and 15.29 to 40.510 days in ICU
Substantial economic burden
cIAI: an Italian study reported that the average cost of care
per patient hospitalised due to cIAI is €4,385 (2009 cost
year)14
cUTI: total costs associated with acute pyelonephritis in the
US in 2000 were estimated to be US$2.14 billion15
HAP (inc. VAP): US studies have reported that hospitalisation
costs are US$30,000 to $40,000 higher for a patient with
VAP than a patient without VAP16-18
• Empiric antibiotic treatment
failure1
• Resistant pathogens2
• Older age3
• Comorbidities19
Substantial mortality
cIAI: reported in-hospital mortality rates range from 4.0%11 to
22.6%20
cUTI: scarce data available
HAP (inc. VAP): reported mortality rates range from 8.9%12 to
35.7%13
Factors contributing to the burden
of cIAI, cUTI and HAP (inc. VAP)
Length of hospital stay increased
*Scarce data are available for cUTI. cIAI, complicated intra-abdominal infection; cUTI, complicated urinary tract infection; ICU, intensive care unit; LOS, length of stay; NP, nosocomial pneumonia; RCT, randomised controlled trial; VAP, ventilator-acquired pneumonia. 1. Dhupar R, et al. Surg Infect (Larchmt). 2012;13:141–146; 2. Bare M, et al. International Journal of Technology Assessment in Health Care. 2006;22:242–248; 3. Barie PS, Rotstein OD, Dellinger EP, Grasela TH, Walawander CA. The cost-effectiveness of cefepime plus metronidazole versus imipenem/cilastatin in the treatment of complicated intra-abdominal infection. Surg Infect (Larchmt). 2004;5:269–280; 4. Montravers P, et al. Annals of Surgery. 2004;239:409–416; 5. Rocha Lde A, et al. The Brazilian Journal of Infectious Diseases 2008;12:80–85; 6. Martin-Loeches I, et al. Intensive Care Medicine. 2013;39:672–681; 7. Suka M, et al. Infection Control and Hospital Epidemiology 2007;28:307–313; 8. Sandiumenge A, et al. Chest. 2011;140:643–651; 9. Mallick R, et al. Surg Infect (Larchmt). 2007;8:159–172; 10. Hu B, et al. Current Medical Research and Opinion. 2010;26:1443–1449; 11. Cattan P, et al. European Journal of Clinical Microbiology & Infectious Diseases. 2002;21:787–793; 12. Sturkenboom M, et al. British Journal of Clinical Pharmacology. 2005;60:438–443; 13. Swenson BR, et al. Surg Infect (Larchmt). 2009;10:29–39; 14. Carson JG, et al. Surg Infect (Larchmt). 2008;9:15–21; 15. Lau WK, et al. Antimicrobial Agents and Chemotherapy. 2006;50:3556–3561; 16. Barie PS, et al. Surg Infect (Larchmt). 2004;5(4):365–373.
• cIAI: mean LOS estimates range from 2.21 to 18.62 days in hospital (see below) and 33 to 114 days in ICU
• HAP (inc. VAP): reported estimates range from 9.25 to 53.46 days in hospital and 15.27 to 40.58 days in ICU
Hospital LOS of patients with cIAI (mean and/or median days) reported in RCTs and observational studies1-3,9-16
Substantial mortality…
Substantial clinical burden cIAI: reported estimates range from 74 to 18.65 days in hospital and 35 to 116 days in ICU
cUTI: scarce data available
NP: reported estimates range from 9.27 to 53.48 days in hospital and 6.89 to 40.510 days in ICU
Reported in-hospital all-cause mortality rates in patients with cIAI1,2,5-13
10.5
18.7
7.6
6.15
22
4
13.8
5.7 6.2
12.1
6.5
22.6
0
5
10
15
20
25
In h
osp
ital a
ll-ca
use
mo
rta
lity
rate
(%
)
Study
• cIAI: reported in-hospital mortality rates range from 4.0%1 to 22.6%2
• HAP (inc. VAP): reported mortality rates range from 6.2%3 to 35.7%4
*Scarce data are available for cUTI. cIAI, complicated intra-abdominal infection; cUTI, complicated urinary tract infection; ICU, intensive care unit; LOS, length of stay; NP, nosocomial pneumonia; RCT, randomised controlled trial; VAP, ventilator-acquired pneumonia. 1. Tellado JM, et al. Scand J Infect Dis. 2007;39:947–955; 2. Barie PS, et al. Surg Infect (Larchmt). 2004;5:365–373; 3. Paladino JA, et al. Journal of the American Geriatrics Society. 2007;55:651–657; 4. Micek ST, et al. Critical Care (London, England). 2015;19:219; 5. Sartelli M, et al. WJES. 2014;9:37; 6. Heizmann WR, et al. The Journal of Antimicrobial Chemotherapy. 2013;68 Suppl 2:ii45–55; 7. Sartelli M, et al. WJES. 2012;7(1):15; 8. Montravers P, et al. Annals of Surgery. 2004;239:409–416; 9. Cattan P, et al. European Journal of Clinical Microbiology & Infectious Diseases 2002;21:787–793; 10. Bodmann KF, et al. Chemotherapy. 2012;58:282–294; 11. Inui T, et al. Surgery. 2009;146(4):654–661; discussion 661–652; 12. Swenson BR, et al. Surg Infect (Larchmt). 2009;10:29–39; 13. Chapman J, et al. Annals of Surgery. 2005;242:576–581; discussion 581–573.
Let’s not forget the fungi: Length of stay…
+62 days (p<0.001)
Haematology
patients without
invasive fungal
infection(n=NR)
Haematology patients
with invasive
fungal infection
(n=NR)
Length of hospital stay (days)*
*Data from a UK prospective study of 203 haematology patients likely to be rendered neutropenic (<0.5x109/L) during treatment from 2008–2010.
Species responsible for infection not listed and may have included non-Aspergillus and Mucorales species.
All high-risk patients (allogeneic haematopoietic stem cell transplant, acute myeloid leukaemia/myelodysplastic syndrome and salvage lymphoma chemotherapies) received
mould-active primary prophylaxis. IA, invasive aspergillosis; NR, not reported.
Ceesay MM et al. J Antimicrob Chemother 2015;70:1175–81.
In untreated mucormycosis, mortality rates can approach 100%1–3
Let’s not forget the fungi: Mortality…
Significant increase in mortality for IA and mucormycosis if prompt & appropriate antifungal cover not given
+34%(p<0.05)
12-week
mortality in
mucormycosis
patients*
(%)1
Timely**
treatment
(n=35)
Delayed†
treatment
(n=35)
*Retrospective chart review study of 70 haematological malignancy patients with mucormycosis from 1989; IA, invasive aspergillosis.
1. Chamilos G et al. Clin Infect Dis 2008;47:503–9;
2. Skiada A et al. Haematologica. 2013;98:492-504;
3. Roden MM et al. Clin Infect Dis. 2005;41:634–53.
<6 days of diagnosis ≥6 days of diagnosis
Let’s not forget the fungi: Costs…
High costs of IA & mucormycosis
Driven by prolonged treatment, increased LOS & ADRs
Mean cost
of care
(£)*1
Haematology patients
without invasive fungal
infection
Haematology patients
with invasive fungal infection
£54,836(p<0.001)
Inpatient stays account for around three quarters of the cost of treating invasive fungal infections
£88,911
£34,075
*Prospective, single-centre cohort analysis of 203 adult haematology patients likely to be rendered neutropenic. Patients followed for median of 18.5 months. Costs are 2010 UK £ and included antifungal
prophylaxis, antifungal treatment, diagnosis and monitoring, and inpatient stays and outpatient visits. The species responsible for invasive fungal infection was not listed. IA, invasive aspergillosis.
Ceesay MM et al. J Antimicrob Chemother 2015;2015:1175–81.
External drivers
https://www.england.nhs.uk/wp-content/uploads/2016/11/cquin-2017-19-guidance.pdf.
Accessed March 2018.
External drivers
https://www.england.nhs.uk/wp-content/uploads/2016/11/cquin-2017-19-guidance.pdf.
Accessed March 2018; CQUIN Indicator Specification Information on CQUIN 2017/18–2018/19.
External drivers
https://www.theguardian.com/society/2016/may/26/uk-doctors-told-to-halve-inappropriate antibiotic-prescriptions-by-
2020. Accessed March 2018; https://www.england.nhs.uk/wp-content/uploads/2016/11/cquin-2017-19-guidance.pdf.
Accessed March 2018; CQUIN Indicator Specification Information on CQUIN 2017/18–2018/19.
2021
How to balance these variables?
Conclusions
Antimicrobial resistance is a global, national, regional & local problem
Increasing resistance brings increasing costs for healthcare
Many components within an AMR control plan
Introduction of new antimicrobials is one element
Current financial climate requires careful evaluation of new agents
Multiple factors involved in pharmacoeconomic evaluation
Some simple, some much more complex
Some universal, some more country/area-specific
Importance of each factor will be user-/organization-dependent
AMR, antimicrobial resistance.
Any questions?
Email: [email protected]